PE20151434A1 - Metodos para la reduccion de los riesgos asociados con el insuficiencia cardiaca y factores asociados con el mismo - Google Patents

Metodos para la reduccion de los riesgos asociados con el insuficiencia cardiaca y factores asociados con el mismo

Info

Publication number
PE20151434A1
PE20151434A1 PE2015000538A PE2015000538A PE20151434A1 PE 20151434 A1 PE20151434 A1 PE 20151434A1 PE 2015000538 A PE2015000538 A PE 2015000538A PE 2015000538 A PE2015000538 A PE 2015000538A PE 20151434 A1 PE20151434 A1 PE 20151434A1
Authority
PE
Peru
Prior art keywords
methods
heart failure
reduction
reduce
risks
Prior art date
Application number
PE2015000538A
Other languages
English (en)
Spanish (es)
Inventor
D Travis Wilson
Hani N Sabbah
Original Assignee
Stealth Peptides Int Inc
Henry Ford Health Systems
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Stealth Peptides Int Inc, Henry Ford Health Systems filed Critical Stealth Peptides Int Inc
Publication of PE20151434A1 publication Critical patent/PE20151434A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/06—Tripeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/07—Tetrapeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C07K5/1019—Tetrapeptides with the first amino acid being basic

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Cardiology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Heart & Thoracic Surgery (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Vascular Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Dermatology (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Emergency Medicine (AREA)
PE2015000538A 2012-10-22 2013-10-22 Metodos para la reduccion de los riesgos asociados con el insuficiencia cardiaca y factores asociados con el mismo PE20151434A1 (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201261716867P 2012-10-22 2012-10-22
US201361822752P 2013-05-13 2013-05-13
US201361839750P 2013-06-26 2013-06-26
US201361839743P 2013-06-26 2013-06-26

Publications (1)

Publication Number Publication Date
PE20151434A1 true PE20151434A1 (es) 2015-10-16

Family

ID=50545459

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2015000538A PE20151434A1 (es) 2012-10-22 2013-10-22 Metodos para la reduccion de los riesgos asociados con el insuficiencia cardiaca y factores asociados con el mismo

Country Status (13)

Country Link
US (4) US20150246092A1 (https=)
EP (5) EP2908839B1 (https=)
JP (3) JP2016503397A (https=)
KR (1) KR20160009008A (https=)
CN (2) CN105050613A (https=)
AU (2) AU2013334788A1 (https=)
BR (1) BR112015009072A2 (https=)
CA (1) CA2889155A1 (https=)
ES (1) ES3058737T3 (https=)
MX (1) MX2015005102A (https=)
NI (1) NI201500057A (https=)
PE (1) PE20151434A1 (https=)
WO (1) WO2014066419A2 (https=)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3626252A1 (en) 2013-03-01 2020-03-25 Stealth Biotherapeutics Corp Methods and compositions for the prevention or treatment of barth syndrome
CN110339339A (zh) 2013-03-01 2019-10-18 康德生物医疗技术公司 治疗线粒体疾病的方法
US10047395B2 (en) * 2013-06-26 2018-08-14 Stealth Biotherapeutics Corp Methods and compositions for detecting and diagnosing diseases and conditions
CA3020393A1 (en) 2016-04-11 2017-10-19 Carnot, Llc Chiral peptides
WO2017223533A1 (en) * 2016-06-24 2017-12-28 University Of Southern California Mentsh analogs as therapeutics for diabetes, obesity, and their associated diseases and complications
KR20200012823A (ko) * 2017-02-01 2020-02-05 예일 유니버시티 이뇨제 내성의 치료
CA3087699A1 (en) 2018-01-05 2019-07-11 Corvidia Therapeutics, Inc. Methods for treating il-6 mediated inflammation without immunosuppression
KR102546547B1 (ko) 2018-01-11 2023-06-22 삼성전자주식회사 보행 보조 방법 및 장치
KR20220052561A (ko) 2020-10-21 2022-04-28 장영진 어류 가공물 및/또는 콩 가공물을 유효성분으로 포함하는 심부전의 예방 또는 치료용 약학 조성물
CN120329388B (zh) * 2025-04-30 2025-09-26 中日友好医院(中日友好临床医学研究所) 一种双靶点多肽及其在心衰治疗中的应用

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
US5858784A (en) 1991-12-17 1999-01-12 The Regents Of The University Of California Expression of cloned genes in the lung by aerosol- and liposome-based delivery
US5716644A (en) 1992-06-11 1998-02-10 Alkermes, Inc. Composition for sustained release of non-aggregated erythropoietin
US5674534A (en) 1992-06-11 1997-10-07 Alkermes, Inc. Composition for sustained release of non-aggregated erythropoietin
US5989463A (en) 1997-09-24 1999-11-23 Alkermes Controlled Therapeutics, Inc. Methods for fabricating polymer-based controlled release devices
US6245740B1 (en) 1998-12-23 2001-06-12 Amgen Inc. Polyol:oil suspensions for the sustained release of proteins
US20040219142A1 (en) * 2002-07-19 2004-11-04 Abbott Laboratories S.A. Treatment of skin and nail disorders using TNFalpha inhibitors
SI2656854T1 (sl) * 2003-02-04 2015-09-30 Cornell Research Foundation, Inc. Uporabe aromatsko-kationskega peptida
EP1890153A1 (en) * 2006-08-16 2008-02-20 F. Hoffman-la Roche AG Cardiac troponin as an indicator of advanced coronary artery disease
EP1890154B1 (en) * 2006-08-16 2012-07-04 F. Hoffmann-La Roche AG Cardiac troponin as an indicator of advanced coronary artery disease
US20080318909A1 (en) * 2007-06-14 2008-12-25 Sparagna Genevieve C Use Of Linoleic Compounds Against Heart Failure
DK2262520T3 (en) * 2008-02-26 2017-08-07 Univ Cornell COMPOSITIONS FOR PREVENTION AND TREATMENT OF Kidney Injury
CN105031605A (zh) * 2009-08-12 2015-11-11 康奈尔大学 预防或治疗代谢综合症的方法
EP2485749A4 (en) * 2009-10-05 2013-07-24 Univ Cornell METHOD FOR THE PREVENTION AND TREATMENT OF HEART FAILURE
WO2011066374A2 (en) * 2009-11-24 2011-06-03 Alder Biopharmaceuticals, Inc. Antagonists of il-6 to prevent or treat cachexia, weakness, fatigue, and/or fever
CN103751763A (zh) * 2009-12-31 2014-04-30 康肽德生物医药技术有限公司 用于预防或治疗血管阻塞损伤的方法
EP3266462A1 (en) * 2009-12-31 2018-01-10 Stealth Peptides International, Inc. Methods for performing a coronary artery bypass graft procedure
EP3332795A1 (en) * 2010-02-26 2018-06-13 Cornell University Cornell Center For Technology, Enterprise & Commercialization ("CCTEC") Mitochondrial-targeted antioxidants protect against mechanical ventilation-induced diaphragm dysfunction and skeletal muscle atrophy
EP3375449A1 (en) * 2010-03-15 2018-09-19 Stealth Peptides International, Inc. Combination therapies using cyclosporine and aromatic cationic peptides
HK1210953A1 (en) * 2012-08-02 2016-05-13 Stealth Peptides International, Inc. Methods for treatment of atherosclerosis
EP2928562A4 (en) * 2012-12-06 2016-06-22 Stealth Peptides Int Inc PEPTIDE THERAPEUTIC PRODUCTS AND METHODS OF USE
WO2014210062A1 (en) * 2013-06-26 2014-12-31 Stealth Peptides International, Inc. Methods for the regulation of matrix metalloproteinase expression
US10047395B2 (en) * 2013-06-26 2018-08-14 Stealth Biotherapeutics Corp Methods and compositions for detecting and diagnosing diseases and conditions

Also Published As

Publication number Publication date
EP4711005A3 (en) 2026-04-22
EP2908839A2 (en) 2015-08-26
JP2019194193A (ja) 2019-11-07
ES3058737T3 (en) 2026-03-12
EP3586862B1 (en) 2021-12-08
CN110193077A (zh) 2019-09-03
CN105050613A (zh) 2015-11-11
JP2018109012A (ja) 2018-07-12
KR20160009008A (ko) 2016-01-25
US20230190859A1 (en) 2023-06-22
EP2908839B1 (en) 2019-08-21
EP3586862A1 (en) 2020-01-01
AU2018206766A1 (en) 2018-08-09
HK1213799A1 (en) 2016-07-15
WO2014066419A2 (en) 2014-05-01
EP4397314A1 (en) 2024-07-10
EP2908839A4 (en) 2016-06-15
WO2014066419A3 (en) 2014-06-12
US20200360462A1 (en) 2020-11-19
US20150246092A1 (en) 2015-09-03
MX2015005102A (es) 2016-02-09
BR112015009072A2 (pt) 2017-07-04
JP2016503397A (ja) 2016-02-04
EP4711005A2 (en) 2026-03-18
EP4005582A1 (en) 2022-06-01
AU2013334788A1 (en) 2015-06-04
EP4397314B1 (en) 2025-12-03
NI201500057A (es) 2015-07-16
US20250255929A1 (en) 2025-08-14
CA2889155A1 (en) 2014-05-01

Similar Documents

Publication Publication Date Title
PE20151434A1 (es) Metodos para la reduccion de los riesgos asociados con el insuficiencia cardiaca y factores asociados con el mismo
UY39119A (es) Proteínas de fusión para tratar trastornos metabólicos
GT201400166A (es) Miméticos de apelina sintéticos para el tratamiento de insuficiencia cardiaca
MX2015013948A (es) Composicion farmaceutica, metodos para tratamiento y sus usos.
CL2016000373A1 (es) Beneficio de supervivencia en pacientes con tumores sólidos con niveles elevados de proteína c reactiva
MX359201B (es) Polipeptidos que se unen al complemento humano 5 (c5).
ES2694667T3 (es) Método para producir oxalato oxidasas que tienen actividad óptica cerca de pH fisiológico y uso de tales oxalato oxidasas recombinantes en el tratamiento de enfermedades relacionadas con oxalato
NI201300143A (es) Coagonista del receptor de glucagón/glp-1
DOP2015000020A (es) Proteínas de fusión para el tratamiento de un síndrome metabólico
CL2015003199A1 (es) Peptidos terapeuticos
MX2016004441A (es) Tratamiento del cancer con una combinacion de plinabulina y taxano.
PH12018502593A1 (en) Combinations of linagliptin and metformin
MX2018007933A (es) Metodo de tratamiento de mamifero, incluido el ser humano, contra cancer usando agotamiento de metionina y asparagina.
GT201500168A (es) Polipéptidos estabilizados del factor de crecimiento tipo insulina
NI201200085A (es) Método para tratar la insuficiencia cardíaca con péptidos tipo estrescopina
MX2017005186A (es) Celulas madre neurales estables que comprenden un polinucleótido exógeno que codifica un factor de crecimiento y métodos de uso de las mismas.
MX389091B (es) Tratamiento de pacientes con diabetes mellitus de tipo 2.
AR103415A1 (es) Tratamiento de pacientes pediátricos con diabetes mellitus de tipo 2
EA201992562A1 (ru) Пептиды для лечения сахарного диабета
CO2019003865A2 (es) Proteína terapéutica
BR112016028561A2 (pt) composição, forma de dosagem, e, métodos para reduzir o risco para mortalidade em um indivíduo, o risco para uma doença ou condição em um indivíduo, triglicerídeos em um sangue de indivíduo, a frequência cardíaca em repouso de um indivíduo, o colesterol de lipoproteína de densidade não alta em um indivíduo, o colesterol total em um indivíduo, a apolipoproteína b em um sangue de indivíduo, pressão sanguínea sistólica em um indivíduo e a pressão sanguínea diastólica em um indivíduo, para prolongar a vida de um indivíduo, para tratar hipertrigliceridemia em um indivíduo e para aumentar um índice de ômega-3 em células vermelhas do sangue de um indivíduo.
CO2017001899A2 (es) Tratamiento del cáncer con el inhibidor de la alfa-amilasa en los animales de compañía
AR102412A1 (es) Composiciones y métodos para el tratamiento con hemopexina
PE20221463A1 (es) Celula vector adyuvante artificial con contenido de ny-eso-1 para usar en el tratamiento del cancer
MX2019002422A (es) Proteina sin fenilalanina para el tratamiento de pku.

Legal Events

Date Code Title Description
FA Abandonment or withdrawal